✦ LIBER ✦

One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy

✍ Scribed by Dan Ziegler; Peter Mayer; Wolfgang Rathmann; F.Arnold Gries

Book ID: 119135177
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 1019 KB
Volume: 14
Category: Article
ISSN: 0168-8227
DOI: 10.1016/0168-8227(91)90054-h

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of diabetic autonomic neuropat

Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor

✍ T. J. C. Faes; G. A. Yff; O. Weerdt; P. Lanting; J. J. Heimans; F. W. Bertelsman 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 511 KB

Epalrestat: An Aldose Reductase Inhibito

Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy

✍ Mary Ann Ramirez; Nancy L. Borja 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Long-term treatment of subclinical diabe

Long-term treatment of subclinical diabetic peripheral neuropathy with aldose reductase inhibitor

✍ F.P. Serra; C. Canale; G. Nolfe; V. Palma; F. Rotondi; C. Serra 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 211 KB

The effect of the aldose reductase inhib

The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy

✍ Carlos Arauz-Pacheco; Luis C. Ramirez; Lourdes Pruneda; George E. Sanborn; Julio 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 887 KB

Aldose reductase inhibitors in the treat

Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review

✍ Kate E. Schemmel; Rosalyn S. Padiyara; Jennifer J. D'Souza 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Clinical and neurophysiological studies

Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy

✍ I. G. Lewin; I. A. D. O'Brien; M. H. Morgan; R. J. M. Corrall 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 436 KB

The effect of sorbinil (200 mg daily for 4 weeks) was examined in 13 patients, mean age 59.7 years (range 42-72 years), with symptomatic diabetic neuropathy of mean duration 6 year (range 1-18 years). In this double-blind, placebo-controlled crossover trial, studies were made of motor, sensory and a